Clinical Evidence 2026 Update: Phase 3 TRIUMPH Data In December 2025, Eli Lilly reported the first successful Phase 3 readout for retatrutide (LY3437943) from the TRIUMPH-4 trial
Personalized Regimens Your health and goals are unique, and so is your peptide plan
The news about how well retatrutide works came this month from Eli Lilly, the drugs manufacturer
We're here to be your partner in that journey, providing the tools and expertise you need to push the boundaries of scientific understanding
Recent research has broadened its applications beyond metabolism, highlighting its synergistic potential with NAD+ therapy for anti-aging and longevity benefits.[6][7] For instance, studies in adipocytes have demonstrated that 5-Amino-1MQ can increase NAD+ levels by 1.2 to 1.6-fold, suggesting a direct role in cellular rejuvenation.[8] This evidence prompted HyperCharge Health to incorporate NAD+ therapy with 5-Amino-1MQ, particularly for adults over 40, where NAD+ levels may have dropped by 50% or more.[9][10] At our clinics, we've observed patients reporting not just improved energy but also enhanced skin elasticity and reduced inflammation markers after combining these therapies
That matters because blood-sugar control does the opposite: HbA1c is nearly maxed out by 10 mg, so the top dose is justified by weight, not by additional glucose lowering. Body size also shifts the felt dose
